- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MacroGenics Inc (MGNX)
MacroGenics Inc stock price live, this page displays NASDAQ MGNX stock exchange data. View the MGNX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the MacroGenics Inc real time stock price chart below.
What Is the MacroGenics Inc Stock Price Today?
The MacroGenics Inc stock price today is 1.83.
What Is the Stock Symbol for MacroGenics Inc?
The stock ticker symbol for MacroGenics Inc is MGNX.
Is MGNX the Same as $MGNX?
$MGNX is a common way to refer to the MacroGenics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does MacroGenics Inc Trade On?
MacroGenics Inc is listed and trades on the NASDAQ stock exchange.
Is MacroGenics Inc a Good Stock to Buy?
Determining whether MacroGenics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current MacroGenics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MGNX quote. (ISIN: US5560991094)
What Is the MacroGenics Inc Stock Price Today?
The MacroGenics Inc stock price today is 1.83.
What Is the Stock Symbol for MacroGenics Inc?
The stock ticker symbol for MacroGenics Inc is MGNX.
Is MGNX the Same as $MGNX?
$MGNX is a common way to refer to the MacroGenics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does MacroGenics Inc Trade On?
MacroGenics Inc is listed and trades on the NASDAQ stock exchange.
Is MacroGenics Inc a Good Stock to Buy?
Determining whether MacroGenics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current MacroGenics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MGNX quote. (ISIN: US5560991094)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.74
1.92
52 wk Range
0.99
3.02
MGNX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.741.92
52 wk Range
0.993.02
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MGNX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
3.40
Upside
+85.79%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
MacroGenics Inc Company Profile
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics Inc SWOT Analysis
Catalysts Ahead | Delve into MacroGenics' near-term growth opportunities, including lorigerlimab Phase 2 data expected in H2 2025 and the initiation of B7-H3 TOP1 ADC Phase 1 expansion. |
Valuation Gap | Trading at approximately 50% discount to projected cash position with analyst price targets around $3, reflecting market uncertainty despite extended financial runway. |
Financial Fortification | A strategic $70M royalty agreement with Sagard extends MacroGenics' runway through 2027, while maintaining eligibility for up to $540M in milestone payments from Incyte partnership. |
Pipeline Pivot | MacroGenics repositions its clinical strategy after discontinuing LORIKEET trial, focusing resources on LINNET trial for platinum-resistant ovarian cancer as a key value driver. |
MacroGenics Inc Earnings Call Summary for Q4/2024
- Q4 2024 EPS of -$0.07 beat expectations of -$0.40; revenue reached $49.4M, surpassing $29.19M forecast
- 2024 total revenue of $150M, up from $58.7M in 2023; net loss increased to $67M due to higher R&D expenses
- Cash balance of $201.7M extends runway into H2 2026; stock rose 4.29% in after-hours trading
- Clinical updates expected in H2 2025, including LORIKET trial data and MGC-26 dose expansion results
- CEO optimistic about 2025 pipeline advancement; CMO highlighted differentiated approach in checkpoint inhibitors
Last Updated: 03/20/2025, 05:29 PM
Read Full TranscriptCompare MGNX to Peers and Sector
Metrics to compare | MGNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMGNXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −0.6x | −0.6x | |
PEG Ratio | −0.07 | 0.07 | 0.00 | |
Price / Book | 1.7x | 2.4x | 2.6x | |
Price / LTM Sales | 0.9x | 9.4x | 3.4x | |
Upside (Analyst Target) | 63.9% | 48.4% | 44.9% | |
Fair Value Upside | Unlock | 10.1% | 6.3% | Unlock |
Analyst Ratings
2 Buy
5 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 3.40
(+85.79% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
0.27 / -0.41
Revenue / Forecast
53.00M / 28.72M
People Also Watch
FAQ
What Is the MacroGenics Inc (MGNX) Stock Price Today?
The MacroGenics Inc stock price today is 1.83
What Stock Exchange Does MacroGenics Inc Trade On?
MacroGenics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for MacroGenics Inc?
The stock symbol for MacroGenics Inc is "MGNX."
What Is the MacroGenics Inc Market Cap?
As of today, MacroGenics Inc market cap is 115.76M.
What Is MacroGenics Inc's Earnings Per Share (TTM)?
The MacroGenics Inc EPS (TTM) is -1.21.
When Is the Next MacroGenics Inc Earnings Date?
MacroGenics Inc will release its next earnings report on Feb 19, 2026.
From a Technical Analysis Perspective, Is MGNX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has MacroGenics Inc Stock Split?
MacroGenics Inc has split 0 times.
How Many Employees Does MacroGenics Inc Have?
MacroGenics Inc has 341 employees.
What is the current trading status of MacroGenics Inc (MGNX)?
As of Feb 02, 2026, MacroGenics Inc (MGNX) is trading at a price of 1.83, with a previous close of 1.93. The stock has fluctuated within a day range of 1.74 to 1.92, while its 52-week range spans from 0.99 to 3.02.
What Is MacroGenics Inc (MGNX) Price Target According to Analysts?
The average 12-month price target for MacroGenics Inc is USD3.40, with a high estimate of USD5 and a low estimate of USD2. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +85.79% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.